Ongoing and Future Clinical Trials of Pharmacotherapy for Heart Failure

Taha Mansoor, Subaina N. Khalid, Muhammad Ibraiz Bilal, Sardar Hassan Ijaz, Marat Fudim, Stephen J. Greene, Haider J. Warraich, Vijay Nambi, Salim S. Virani, Gregg C. Fonarow, Dmitry Abramov, Abdul Mannan Khan Minhas

Research output: Contribution to journalReview articlepeer-review


Increasing knowledge of the processes leading to heart failure (HF) has allowed significant developments in therapies for HF over the past few decades. Despite the evolution of HF treatment, it still places a large burden on patients and health care systems across the world. We used to gather information about clinical trials as of August 2023 studying pharmacotherapy for HF. We included interventional trials that were “active, not recruiting”, “recruiting”, or looking for participants but “not yet recruiting”. In total, 119 studies met our criteria of ongoing clinical trials studying novel as well as currently approved HF pharmacotherapies. The major interventions were novel medications/already approved medications for other diseases 29 % (34 trials), sodium-glucose co-transporter inhibitors 21 % (25 trials), angiotensin receptor blocker-neprilysin inhibitors 10 % (12 trials), diuretics 14 % (17 trials) and mineralocorticoid receptor antagonists 5 % (6 trials). Ongoing research will aid in reducing the impact of HF and we summarize clinical trials leading the way to better HF treatment in this review.

Original languageEnglish
JournalAmerican Journal of Cardiovascular Drugs
Publication statusAccepted/In press - 2024


Dive into the research topics of 'Ongoing and Future Clinical Trials of Pharmacotherapy for Heart Failure'. Together they form a unique fingerprint.

Cite this